Jung Min Kim
About Jung Min Kim
Jung Min Kim is a Senior Principal Scientist at Bristol Myers Squibb with extensive experience in drug discovery and protein engineering.
Title and Current Position
Jung Min Kim holds the position of Senior Principal Scientist at Bristol Myers Squibb. This role involves overseeing and contributing to advanced research projects, particularly in the field of protein and cytokine engineering, reinforcing the company's drug discovery initiatives.
Career at Bristol Myers Squibb
Jung Min Kim began working at Bristol Myers Squibb in 2019 as Principal Scientist, a role he held for one year. Following this, he was promoted to Senior Principal Scientist. During his tenure, he led a team that developed novel protein and cytokine engineering techniques, and served as project lead on multiple drug discovery projects.
Previous Industry Experience
Prior to his current role, Jung Min Kim worked at Celgene as a Senior Scientist from 2017 to 2019, and at Delinia (acquired by Celgene) as a Senior Scientist from 2016 to 2017. Additionally, he worked at Compugen Inc. as a Scientist from 2014 to 2016. These roles were primarily based in the San Francisco Bay Area and involved significant contributions to research and development in the pharmaceutical and biotechnology sectors.
Academic Background and Research
Jung Min Kim's academic career includes significant time at the University of Toronto and the University of California, San Francisco. He obtained his Ph.D. in Molecular Genetics from the University of Toronto, where he also earned a B.Sc. in Biochemistry Specialist & Math Minor. As a Postdoctoral Scholar at the Craik Lab in UCSF, he worked on notable research projects, further strengthening his expertise in molecular genetics and biochemistry.
Contributions to Scientific Research
Jung Min Kim has made substantial contributions to the field of scientific research. At the Craik Lab at UCSF, he engaged in important research projects. His impactful work at Delinia contributed to the company's acquisition by Celgene. His extensive experience spans across both academic and industry settings, providing him with a broad perspective on scientific research and development.